Basel, 10 July 2017 Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87% compared with on-demand bypassing agents All 12 secondary endpoints in HAVEN 1 were positive, including an intra-patient comparison that showed emicizumab reduced bleed rate... Read more
On July 7, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) recommended to suspend broad spectrum intravenous use of linear gadolinium agents except for select indication of liver imaging. The PRAC’s recommendation applies to Europe only and is not https://www.genewsroom.com/press-releases/message-our-customers-about-pharmacovigilance-risk-assessment-committee Read more
Developed to support assay development and validation for detection of anti-drug antibodies Uppsala, Sweden, June 29th, 2017: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced it has launched a new version of its anti-drug antibody (ADA) solution for the immunogenicity market. ... Read more
Chalfont St. Giles, UK and Plankstadt, Germany – June 28, 2017 – CordenPharma International and GE Healthcare’s Dharmacon business have entered a strategic collaboration to create an end-to-end solution for oligonucleotide-based drug discovery. The collaboration will address the speed and capacity challenges researchers face when transitioning from research and preclinical stages to drug development and... Read more
Basel, 26 June 2017 Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Emicizumab showed substantial and clinically meaningful reduction in bleeds across two pivotal studies Data from HAVEN 1 in adults and adolescents and interim data from HAVEN 2 in children to be presented... Read more
Basel, 26 June 2017 Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Emicizumab showed substantial and clinically meaningful reduction in bleeds across two pivotal studies Data from HAVEN 1 in adults and adolescents and interim data from HAVEN 2 in children to be presented... Read more
Jun 19, 2017 Microsaic Systems plc (AIM: MSYS), the developer of chip-based mass spectrometry (“MS”) instruments designed to improve the efficiency of pharmaceutical R&D, announces the following unaudited trading update as it approaches the end of the six month period to 30 June 2017. The Company advised the market on 13 December 2016 that it... Read more
Scientists facing highly complex characterization challenges can now gain a deeper understanding of their samples with new enhancements to the industry-leading Thermo Scientific Orbitrap Fusion Lumos Tribrid mass spectrometer that extend its power, performance and versatility. “When we launched the Orbitrap Fusion Lumos Tribrid mass spectrometer at ASMS two years ago, we redefined protein and... Read more
Basel, 05 June 2017 Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Second positive phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa... Read more